drugset / Trial / NCT07078591
Venetoclax-containing Therapy Combined With Microtransplant for Newly Diagnosed AML
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate whether HLA-mismatched donor G-CSF mobilized peripheral blood mononuclear cell (GPBMC) infusion with venetoclax-containing regimens (microtransplant, MST) could improve survival in adult patients with newly diagnosed acute myeloid leukemia (AML).
Timeline
- Start
- 2025-06-20
- Primary completion
- 2030-06
- Completion
- 2031-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Azacitidine | Other / unclassified | 75 mg/m2 | Subcutaneous |
| Subject | Cytarabine | Small molecule | 100 mg/m2 | Intravenous |
| Subject | Cytarabine | Small molecule | 1000 mg/m2 | Intravenous |
| Subject | Cytarabine | Small molecule | 1500 mg/m2 | Intravenous |
| Subject | Daunorubicin | Small molecule | 60 mg/m2 | Intravenous |
| Subject | Idarubicin | Small molecule | 12 mg/m2 | Intravenous |
| Subject | Venetoclax | Small molecule | 400 mg | Oral |